New Trade Alert: Genprex, Inc. (NASDAQ: $GNPX)
Post# of 18442
(Total Views: 515)
Posted On: 04/25/2018 9:50:55 AM
New Trade Alert: Genprex, Inc. (NASDAQ: $GNPX)
Since we last alerted GNPX, the company has traded range bound yet has announced a number of breaking developments in the past few weeks.
As a reminder, GNPX is a newly listed NASDAQ company that became public just a few weeks ago and is seeking to disrupt the cancer treating industry.
Each year there are over 1.8 million new lung cancer cases and 1.6 million deaths from lung cancer worldwide, and in the United States there are over 225,000 new cases and more than 150,000 deaths from lung cancer per year. Non-small cell lung cancer (NSCLC) represents 80% of all lung cancers.
Despite great advancements in medical technology and drug development, according to a 2016 American Cancer Society Report, the five-year survival rate for Stage IV (metastatic) NSCLC is about 1%.
As a result, targeted cancer therapy is starting to gain favor over conventional chemotherapies in some clinical oncology practices.
“Genprex technologies are being developed to overcome genomic limitations” existing “in targeted therapies and provide new treatment solutions to large cancer patient populations.”
http://www.mybeststockpicks.com/gnpx-joins-he...al-school/
Since we last alerted GNPX, the company has traded range bound yet has announced a number of breaking developments in the past few weeks.
As a reminder, GNPX is a newly listed NASDAQ company that became public just a few weeks ago and is seeking to disrupt the cancer treating industry.
Each year there are over 1.8 million new lung cancer cases and 1.6 million deaths from lung cancer worldwide, and in the United States there are over 225,000 new cases and more than 150,000 deaths from lung cancer per year. Non-small cell lung cancer (NSCLC) represents 80% of all lung cancers.
Despite great advancements in medical technology and drug development, according to a 2016 American Cancer Society Report, the five-year survival rate for Stage IV (metastatic) NSCLC is about 1%.
As a result, targeted cancer therapy is starting to gain favor over conventional chemotherapies in some clinical oncology practices.
“Genprex technologies are being developed to overcome genomic limitations” existing “in targeted therapies and provide new treatment solutions to large cancer patient populations.”
http://www.mybeststockpicks.com/gnpx-joins-he...al-school/
(0)
(0)